“We are encouraged by the opportunity to build on this with an expected regulatory decision for patients with cisplatin-eligible MIBC.”

In context

“rtant year in a pivotal investment period as we strive for industry-leading growth after several key products lose patent or regulatory exclusivity in the next few years. Albert Bourla: Seagen, Metaira, and Biohaven are the most significant strategic acquisitions in recent years. They have transformative potential for Pfizer Inc., and we are focused on maximizing the value of in-line product portfolios and accelerating pipeline development. We made continued progress last year integrating legacy Seagen products into our commercial portfolio. I'm also pleased with notable advances in our development programs, including recent FDA approval for PATCEV in combination with pembrolizumab for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapies. We are encouraged by the opportunity to build on this with an expected regulatory decision for patients with cisplatin-eligible MIBC. If successful, we will substantially expand the US addressable population with approximately 22,500 additional patients across both cis-eligible and cis-ineligible muscle-invasive bladder cancer, up from about 19,000 patients in metastatic urothelial cancer. We have a clear strategy aiming for Pfizer Inc. leadership in the next generation of therapies for chronic weight management with a highly differentiated Metsera pipeline portfolio, our Yaopharm exclusive global collaboration and licensing agreement, and other Pfizer Inc. programs such as our oral GPR antagonist candidate. Since closing our Biohaven acquisition a few years ago, we have globally scaled a leading migraine portfolio. It strengthened our product mix to drive significant impact both for patients and our commercial performa”